Trastuzumab Lyophilized Powder Concentrate Solution Infusion

Name: Trastuzumab Lyophilized Powder Concentrate Solution Infusion
Brand: Vikshar Healthcare Private Limited
Price: 234.18 INR
Availability: InStock

Price 234.18 INR/ Piece

Get a Price/Quote

MOQ : 1 Piece

Trastuzumab Lyophilized Powder Concentrate Solution Infusion Specification

Indication
HER2-positive cancers

Pacakaging (Quantity Per Box)
1 vial per box

Life Span
Refer to package

Dosage Form
Infusion solution

Brand Name
Trazumab

Packaging Type
Vial

Origin of Medicine
India

Salt Composition
Trastuzumab

Drug Type
Prescription

Ingredients
Trastuzumab

Physical Form
Lyophilized Powder

Function
Anticancer agent

Recommended For
Breast, esophageal, stomach cancer

Dosage
150mg per vial

Dosage Guidelines
As directed by physician

Suitable For
Adults

Quantity
1 vial

Storage Instructions
Store below 30C

Grade
Medicine Grade

Language Support
English, Hindi

Concentration
Multi-use vial

Prescription
Required

Form
Injection

Strength
150mg

Administration Route
IV infusion

Packaging Size
7.2mL

Trastuzumab Lyophilized Powder Concentrate Solution Infusion Trade Information

Minimum Order Quantity
1 Piece

Supply Ability
500 Pieces Per Month

Delivery Time
7 Days

Trastuzumab Lyophilized Powder Concentrate Solution Infusion About

Redeem your chance at advanced cancer care with Trazumab, a renowned Trastuzumab Lyophilized Powder Concentrate Solution. This valiant, medicine-grade anticancer agent is decorated for treating HER2-positive breast, esophageal, and stomach cancers in adults. Available in a 150mg multi-use vial, each package includes 7.2mL infusion solution for IV administration. Limited stock available for a limited time. Supplied with English and Hindi language support, these prescription-only vials are sourced from India's trusted exporters. Store below 30C. Dosage is 150mg per vial, as directed by physicians.

Trastuzumab Infusion: Proper Use and Administration

Trazumab Trastuzumab Lyophilized Powder is designed for intravenous infusion, specifically recommended for adults with HER2-positive cancers. Usage must strictly follow the prescribed dosage-typically 150mg per vial-administered by healthcare professionals. The solution is prepared by reconstituting the powder and delivering it through an IV line. The treated site is intravenous, maximizing targeted action against affected cells. Always adhere to your physician's direction for safe, effective cancer therapy outcomes.

Supply Ability & Global Distribution

Packing & Dispatch of Trazumab are conducted with strict quality control, ensuring secure transport services and timely delivery. Certified under top medical standards, each vial is securely packaged for export, with one vial per box for safe handling. Our extensive distribution network covers main export markets, facilitating smooth exchange processes with reliable logistics support. We excel in providing steady supply ability, serving healthcare facilities across multiple continents efficiently.

FAQ's of Trastuzumab Lyophilized Powder Concentrate Solution Infusion:

Q: How should Trastuzumab Lyophilized Powder Concentrate Solution be administered?

A: This medication is administered as an intravenous (IV) infusion, typically within a clinical setting and under the supervision of qualified medical personnel.

Q: What cancers does Trazumab (Trastuzumab) treat?

A: Trazumab is recommended for HER2-positive breast, esophageal, and stomach cancers in adults as directed by a physician.

Q: When is it necessary to use Trazumab?

A: Trazumab is prescribed when a patient has been diagnosed with HER2-positive cancers. The timing and frequency follow your oncologist's specific instructions.

Q: Where can this medicine be purchased?

A: Trazumab is available through licensed pharmacies and authorized exporters, suppliers, or traders across India, with one vial per box packaging.

Q: What are the key benefits of using Trastuzumab Lyophilized Powder?

A: Trastuzumab targets HER2-positive cancer cells, helping to slow growth and improve long-term outcomes as part of a comprehensive cancer treatment plan.